Portola Pharmaceuticals Inc (NASDAQ:PTLA) has been given a consensus recommendation of “Buy” by the ten analysts that are covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $43.50.
Several equities analysts have commented on the stock. Cowen restated a “buy” rating and issued a $45.00 price target on shares of Portola Pharmaceuticals in a research note on Thursday, August 8th. Credit Suisse Group reissued a “neutral” rating and issued a $35.00 price target on shares of Portola Pharmaceuticals in a research report on Monday, August 5th. ValuEngine cut shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Zacks Investment Research cut shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Finally, BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 17th.
Shares of NASDAQ:PTLA traded down $1.01 during trading on Friday, reaching $27.80. 1,072,409 shares of the company’s stock traded hands, compared to its average volume of 1,583,458. Portola Pharmaceuticals has a fifty-two week low of $14.81 and a fifty-two week high of $37.95. The company has a quick ratio of 3.61, a current ratio of 3.63 and a debt-to-equity ratio of 453.47. The firm has a market cap of $1.97 billion, a PE ratio of -5.55 and a beta of 2.18. The company has a 50-day simple moving average of $27.45 and a 200-day simple moving average of $30.33.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.05) by $0.13. Portola Pharmaceuticals had a negative net margin of 379.94% and a negative return on equity of 352.12%. The business had revenue of $28.42 million for the quarter, compared to analyst estimates of $25.42 million. During the same period last year, the company posted ($1.61) EPS. The business’s revenue was up 608.7% on a year-over-year basis. On average, equities research analysts forecast that Portola Pharmaceuticals will post -3.83 EPS for the current year.
In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the transaction, the director now directly owns 18,194 shares in the company, valued at $545,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.50% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in PTLA. Vanguard Group Inc. lifted its stake in shares of Portola Pharmaceuticals by 2.6% during the second quarter. Vanguard Group Inc. now owns 5,985,834 shares of the biopharmaceutical company’s stock valued at $162,396,000 after buying an additional 151,150 shares during the period. BlackRock Inc. lifted its stake in shares of Portola Pharmaceuticals by 3.6% during the second quarter. BlackRock Inc. now owns 5,324,948 shares of the biopharmaceutical company’s stock valued at $144,466,000 after buying an additional 186,304 shares during the period. William Blair Investment Management LLC lifted its stake in shares of Portola Pharmaceuticals by 20.3% during the second quarter. William Blair Investment Management LLC now owns 4,997,224 shares of the biopharmaceutical company’s stock valued at $135,575,000 after buying an additional 842,354 shares during the period. Cadian Capital Management LP lifted its stake in shares of Portola Pharmaceuticals by 2.9% during the second quarter. Cadian Capital Management LP now owns 4,091,687 shares of the biopharmaceutical company’s stock valued at $111,007,000 after buying an additional 116,789 shares during the period. Finally, Fiera Capital Corp purchased a new position in shares of Portola Pharmaceuticals during the first quarter valued at approximately $53,590,000.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Further Reading: What is Elliott Wave theory?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.